Cell impermeable kinase inhibitors to treat sars-cov-2 and/or hsv viral infections
AssigneeAlbert Einstein College of Medicine
InventorsBetsy C. Herold, Steven C. Almo
Life of this patent
Estimating the term…
Abstract
Methods of preventing or treating a coronavirus infection or a herpes simplex virus infection in a subject or preventing or treating a disease caused by a coronavirus infection or a herpes simplex virus infection in a subject are disclosed. The methods comprise administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 (PDPK1) inhibitor, an anti-PDPK1 antibody, or a combination thereof.
Claims24
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 (PDPK1) inhibitor, an anti-PDPK1 antibody, or a combination thereof for inhibiting or treating a coronavirus infection in a subject or for preventing or treating a disease caused by a coronavirus infection in a subject.
A method of preventing or treating a coronavirus infection in a subject or preventing or treating a disease caused by a coronavirus infection in a subject, comprising administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 (PDPK1) inhibitor, an anti-PDPK1 antibody, or a combination thereof.
7-8. (canceled)
A method of preventing or treating a condition, a disorder or a disease associated with a SARS-CoV-2 infection in a subject comprising administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 inhibitor, or a combination thereof.
(canceled)
A method of preventing or treating a herpes simplex virus infection in a subject or preventing or treating a disease caused by a herpes simplex virus infection in a subject, comprising administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 (PDPK1) inhibitor, an anti-PDPK1 antibody, or a combination thereof.
(canceled)
(canceled)
Dependencies are inferred from the claim text.